Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
| Revenue (Most Recent Fiscal Year) | $4.90M |
| Net Income (Most Recent Fiscal Year) | $-173.80M |
| PE Ratio (Current Year Earnings Estimate) | 11.02 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 36.96 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3467.04% |
| Net Margin (Trailing 12 Months) | -3467.04% |
| Return on Equity (Trailing 12 Months) | -12.24% |
| Return on Assets (Trailing 12 Months) | 32.16% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.11 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-6.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.27 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $-7.60 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.18M |
| Free Float | 5.76M |
| Market Capitalization | $204.87M |
| Average Volume (Last 20 Days) | 0.12M |
| Beta (Past 60 Months) | 1.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 84.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.57% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |